Validation Study of the SAGIT® Instrument in Acromegaly (SAGIT)
International Multicentre Validation Study of SAGIT® Instrument in Acromegaly
Patients will be treated in accordance with the standard medical practice of the hospital where they have been recruited during their participation in this study. No additional assessments or tests will be required.
SAGIT® is a new instrument developed by a group of acromegaly experts to help practicing endocrinologists to manage acromegalic patients and disease activity in their clinical practice and define acromegaly staging. It reports 5 elements: Signs and symptoms - S; Associated comorbidities - A; Growth hormone (GH) concentration - G; Insulin-like growth factor 1(IGF-1) concentration -I; Tumour size- T.
The instrument has been pre evaluated during a qualitative pilot study. The purpose of the validation study is to define and validate the scoring of the SAGIT® instrument.
研究概览
地位
条件
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Aarhus C、丹麦、8000
- Department of Clinical Medicine - The Department of Endocrinology and Diabetes
-
Copenhagen、丹麦、2100
- University Hospital, Dept of Endocrinology
-
-
-
-
-
Rio de Janeiro、巴西、21941-913
- Federal University of Rio de Janeiro
-
Sao Paulo、巴西
- University Hospital
-
São Paulo、巴西、0503900
- University Hospital
-
-
-
-
-
Essen、德国、45147
- University Hospital
-
Hamburg、德国、20357
- Endoc Zentrum Fûr Endokrine Tumoren
-
Oldenburg、德国、26122
- Private Clinique
-
-
-
-
-
Montichiari、意大利、25018
- Ospedaliera Spedali Civili di Brescia
-
Naples、意大利
- Azienda Ospedaliero Universitar a Fedderico II
-
Padova、意大利
- Azienda Ospedaliera di Padova
-
Pisa、意大利
- Azienda Ospedaliero Universitaria Pisana-Endcrinologia 2
-
Rome、意大利、00168
- Endocrinology, University Hospital, Policlinica Gemelu
-
-
-
-
-
Liège、比利时
- CHU de Liege
-
-
-
-
-
Bron、法国、69677
- Hopital Neuro-cardiologique
-
Le Kremlin-Bicêtre、法国、94275
- Hopital de Bicetre
-
Marseille、法国、13385
- CHU de Marseille - Hôpital de la Timone
-
Toulouse、法国、31400
- CHU Larrey
-
-
-
-
California
-
Los Angeles、California、美国、90048
- Cedars-Sinai Medical Center
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- The Emory Pituitary Center
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- Cleveland Clinic
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15212
- Endocrinology and Metabolism
-
-
-
-
-
Aberdeen、英国
- Aberdeen Royal Infirmary
-
Cambridge、英国
- University Hospital
-
Cardiff、英国
- Université Hospital
-
Oxford、英国
- Endocrinology and Metabolism Churchill Hospital
-
-
-
-
-
Leiden、荷兰、2333 2A
- LUMC Leiden,
-
Nijmegen、荷兰
- Radbound UMC
-
Rotterdam、荷兰、3000 CA
- Erasmus MC
-
-
-
-
-
Barcelona、西班牙
- University Hospital
-
Madrid、西班牙、28046
- University Hospital
-
Santiago de Compostela、西班牙
- Hospital de Condia(CHUS) RVA Ramon Baltar S/N
-
Sevilla、西班牙、41013
- University Hospital Virgen del Rocio
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Male or female aged 18 years-old or above at study inclusion
- Treatment-naïve and non treatment-naïve patients with a diagnosis of acromegaly
- Data required to complete the SAGIT® tool are available in the patient medical records and do not require additional assessments or tests
- Data required to complete the SAGIT® tool are recorded within the 3 months preceding the inclusion visit (6 months for MRI)
Exclusion Criteria:
- Acute uncontrolled disease requiring intensive care
学习计划
研究是如何设计的?
设计细节
- 观测模型:队列
- 时间观点:其他
队列和干预
团体/队列 |
---|
Controlled
|
Not controlled
|
Control status yet to be clarified
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Define and validate the scoring of the SAGIT® instrument
大体时间:baseline
|
Evaluating the ability of the instrument to discriminate subgroups of subjects with acromegaly (controlled vs not controlled).
|
baseline
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
The ability of the SAGIT® instrument to predict the occurrence of significant clinical event(s) and/or treatment change(s) over time.
大体时间:2 years
|
Significant clinical event is defined as death, stroke, onset of diabetes, onset of arthritis/onset of arthritis disability, myocardial infarction and/or diagnosis of other tumor; treatment change is defined as change in therapeutic doses, in therapeutic drug class, surgery or radiotherapy.
|
2 years
|
Define SAGIT® characteristics for different groups
大体时间:2 years
|
Controlled vs. non controlled.
Treatment-naïve, patients vs. currently treated vs. previously treated patients
|
2 years
|
The association between the SAGIT® tool and patients' quality of life measured using Acromegaly Quality of Life (AcroQoL) scores.
大体时间:2 years
|
Acromegaly Quality of Life (AcroQoL) scores will be compared between patient groups defined according to SAGIT scoring algorithm (controlled vs. not controlled).
This comparison will be performed using t-tests for each available visit of the prospective population.
|
2 years
|
合作者和调查者
赞助
出版物和有用的链接
一般刊物
- Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, Houchard A, Melmed S. International Multicenter Validation Study of the SAGIT(R) Instrument in Acromegaly. J Clin Endocrinol Metab. 2021 Nov 19;106(12):3555-3568. doi: 10.1210/clinem/dgab536.
- Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, Houchard A, Melmed S. Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT(R) validation study. Pituitary. 2019 Oct;22(5):476-487. doi: 10.1007/s11102-019-00977-5.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.